# Mark A Schroeder

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 83 papers | 2,645 citations | 257450 24 h-index | 197818 49 g-index |
| 84 all docs | 84 docs citations | 84 times ranked | 4517 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Machine learningâ€“based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. Blood Advances, 2022, 6, 1991-2000. | 5.2 | 11 |
| 2 | Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplantation, 2022, 57, 31-37. | 2.4 | 4 |
| 3 | Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood, 2022, 139, 1177-1183. | 1.4 | 41 |
| 4 | Mouse models of graft-versus-host disease. Methods in Cell Biology, 2022, 168, 41-66. | 1.1 | 1 |
| 5 | Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematology,the, 2022, 9, e14-e25. | 4.6 | 27 |
| 6 | Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Science Translational Medicine, 2022, 14, eabm1375. | 12.4 | 49 |
| 7 | Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy. Haematologica, 2022, 107, 1709-1713. | 3.5 | 2 |
| 8 | Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. Bone Marrow Transplantation, 2022, 57, 975-981. | 2.4 | 3 |
| 9 | A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. Leukemia and Lymphoma, 2021, 62, 1441-1449. | 1.3 | 2 |
| 10 | Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78. Bone Marrow Transplantation, 2021, 56, 2016-2018. | 2.4 | 2 |
| 11 | A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. Leukemia and Lymphoma, 2021, 62, 3043-3046. | 1.3 | 1 |
| 12 | A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 2477-2488. | 2.4 | 8 |
| 13 | Ruxolitinib resistance or intolerance in steroidâ€refractory acute graftâ€versus â€host disease â€” a realâ€world outcomes analysis. British Journal of Haematology, 2021, 195, 429-432. | 2.5 | 6 |
| 14 | Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leukemia Research, 2021, 110, 106713. | 0.8 | 9 |
| 15 | Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. JCO Precision Oncology, 2021, 5, 191-203. | 3.0 | 4 |
| 16 | A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis. Blood, 2021, 138, 169-169. | 1.4 | 4 |
| 17 | Financial Toxicity Among Patients with Multiple Myeloma. Blood, 2021, 138, 4027-4027. | 1.4 | 2 |
| 18 | SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001). Blood, 2021, 138, 2740-2740. | 1.4 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma. Bone Marrow Transplantation, 2020, 55, 1188-1190. | 2.4 | 1 |
| 20 | Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. Cancer Discovery, 2020, 10, 1854-1871. | 9.4 | 83 |
| 21 | Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood, 2020, 135, 1739-1749. | 1.4 | 176 |
| 22 | The effect of donor type on outcomes in adults with acute myeloid leukemia after reducedâ€intensity hematopoietic peripheral blood cell transplant â€“ a retrospective study. Transplant International, 2020, 33, 1089-1098. | 1.6 | 1 |
| 23 | Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica, 2020, 105, e404-e407. | 3.5 | 16 |
| 24 | Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease. Therapeutic Advances in Hematology, 2020, 11, 204062072091448. | 2.5 | 19 |
| 25 | DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. Annals of Hematology, 2020, 99, 1041-1048. | 1.8 | 12 |
| 26 | A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119). Blood, 2020, 136, 50-51. | 1.4 | 5 |
| 27 | A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma. Blood, 2020, 136, 31-32. | 1.4 | 0 |
| 28 | Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. Blood, 2020, 136, 21-22. | 1.4 | 0 |
| 29 | EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 744-750. | 0.4 | 7 |
| 30 | A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. Clinical Cancer Research, 2019, 25, 7004-7013. | 7.0 | 32 |
| 31 | Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 285-289. | 0.4 | 17 |
| 32 | A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e588-e593. | 0.4 | 6 |
| 33 | A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2019, 25, 3776-3783. | 7.0 | 14 |
| 34 | Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS. Blood, 2019, 134, 3915-3915. | 1.4 | 6 |
| 35 | Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5701-5701. | 1.4 | 0 |
| 36 | Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clinical Cancer Research, 2018, 24, 2294-2303. | 7.0 | 87 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia, 2018, 32, 2483-2494. | 7.2 | 61 |
| 38 | The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 1125-1134. | 2.0 | 73 |
| 39 | A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clinical Cancer Research, 2018, 24, 3519-3527. | 7.0 | 80 |
| 40 | Modeling Chronic Graft Versus Host Disease in Mice Using Allogeneic Bone Marrow and Splenocyte Transfer. Current Protocols in Pharmacology, 2018, 83, e47. | 4.0 | 5 |
| 41 | Glasdegib in combination with cytarabine and daunorubicin in patients with AML or highâ€risk MDS: Phase 2 study results. American Journal of Hematology, 2018, 93, 1301-1310. | 4.1 | 98 |
| 42 | Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e363-e364. | 0.4 | 4 |
| 43 | Transfer of Cell-Surface Antigens by Scavenger Receptor CD36 Promotes Thymic Regulatory T Cell Receptor Repertoire Development and Allo-tolerance. Immunity, 2018, 48, 923-936.e4. | 14.3 | 54 |
| 44 | Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study. Blood, 2018, 132, 5666-5666. | 1.4 | 1 |
| 45 | Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance. Blood, 2018, 132, 5277-5277. | 1.4 | 0 |
| 46 | The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma. Blood, 2018, 132, 4463-4463. | 1.4 | 0 |
| 47 | Disparities in Healthcare Resource Utilization for Multiple Myeloma. Blood, 2018, 132, 4793-4793. | 1.4 | 1 |
| 48 | Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma. Blood, 2018, 132, 5627-5627. | 1.4 | 1 |
| 49 | The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients. Blood, 2018, 132, 3439-3439. | 1.4 | 0 |
| 50 | T Cellâ€“Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 648-653. | 2.0 | 38 |
| 51 | Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo. Journal of Immunology, 2017, 198, 3746-3754. | 0.8 | 31 |
| 52 | Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood, 2017, 129, 2680-2692. | 1.4 | 66 |
| 53 | Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10â€day decitabine regimen. Cancer Medicine, 2017, 6, 2814-2821. | 2.8 | 21 |
| 54 | Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2017, 23, 2065-2069. | 2.0 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 1736-1743. | 2.0 | 44 |
| 56 | Chemotherapy versus Hypomethylating Agents forÂtheÂTreatment of Relapsed Acute Myeloid Leukemia andÂMyelodysplastic Syndrome after Allogeneic StemÂCellÂTransplant. Biology of Blood and Marrow Transplantation, 2016, 22, 1324-1329. | 2.0 | 35 |
| 57 | Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review. Biology of Blood and Marrow Transplantation, 2016, 22, 1696-1701. | 2.0 | 50 |
| 58 | The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review. Biology of Blood and Marrow Transplantation, 2016, 22, 1552-1564. | 2.0 | 59 |
| 59 | Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 1137-1141. | 2.0 | 11 |
| 60 | Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Leukemia Research, 2016, 49, 1-6. | 0.8 | 31 |
| 61 | TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036. | 27.0 | 663 |
| 62 | Severe Cytokine-Release Syndrome after T Cellâ€“Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Antiâ€“IL-6 Therapy Is Safe and Well Tolerated. Biology of Blood and Marrow Transplantation, 2016, 22, 1851-1860. | 2.0 | 135 |
| 63 | A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD). Blood, 2016, 128, 390-390. | 1.4 | 15 |
| 64 | Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS. Blood, 2016, 128, 4658-4658. | 1.4 | 0 |
| 65 | Do somatic mutations in de novo MDS predict for response to treatment?. Hematology American Society of Hematology Education Program, 2015, 2015, 317-328. | 2.5 | 5 |
| 66 | Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. Biology of Blood and Marrow Transplantation, 2015, 21, 1425-1430. | 2.0 | 12 |
| 67 | A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results. Blood, 2015, 126, 1935-1935. | 1.4 | 2 |
| 68 | Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes. Blood, 2015, 126, 1950-1950. | 1.4 | 5 |
| 69 | Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. Blood, 2015, 126, 689-689. | 1.4 | 1 |
| 70 | Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 3144-3144. | 1.4 | 0 |
| 71 | Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2014, 20, 46-52. | 2.0 | 86 |
| 72 | Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation. Blood, 2014, 124, 2557-2557. | 1.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 2456-2456. | 1.4 | 1 |
| 74 | Impact of Remission Status on Outcomes in AML Patients â‰¥ 60 Years of Age after Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 1263-1263. | 1.4 | 0 |
| 75 | Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 850-850. | 1.4 | 0 |
| 76 | A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. Blood, 2013, 122, 3931-3931. | 1.4 | 0 |
| 77 | Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. Blood, 2013, 122, 2816-2816. | 1.4 | 0 |
| 78 | Myeloid Suppressive Cells Mobilized by GM-CSF in Non-Tumor Bearing Mice Are Dependent On Interferon Gamma for Function. Blood, 2012, 120, 832-832. | 1.4 | 1 |
| 79 | Mouse models of graft-versus-host disease: advances and limitations. DMM Disease Models and Mechanisms, 2011, 4, 318-333. | 2.4 | 238 |
| 80 | Mobilization of hematopoietic stem and leukemia cells. Journal of Leukocyte Biology, 2011, 91, 47-57. | 3.3 | 34 |
| 81 | Evidence-Based Mini-Review: Should Patients Over the Age of 60 with INT-2 or High-Risk Myelodysplastic Syndrome Undergo Allogeneic Stem Cell Transplantation Prior to Progression to Acute Myelogenous Leukemia?. Hematology American Society of Hematology Education Program, 2010, 2010, 322-324. | 2.5 | 0 |
| 82 | Forced Expression of the â€œIYâ€•Mutant Inosine Monophosphate Dehydrogenase II Results in Physiologically Significant Resistance to Mycophenolic Acid In Vitro.. Blood, 2006, 108, 5480-5480. | 1.4 | 0 |
| 83 | Inosine Monophosphate Dehydrogenase II Mutant (Thr-333-Ile + Ser-351-Tyr) Does Not Confer Resistance to Mycophenolic Acid In Vivo.. Blood, 2005, 106, 5226-5226. | 1.4 | 0 |